Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

Wearable Technologies for Parkinson’s Disease: Exploring Their Clinical Potential

Caitríona L Cox, Alistair J Mackett

Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages of the disease), troubling side effects associated with the available pharmacological treatments, a lack of effective disease-modifying therapies […]

touchREVIEWS in Neurology. 2024;20(2):Online ahead of journal publication

Wearable Technologies for Parkinson’s Disease: Exploring Their Clinical Potential

Caitríona L Cox, Alistair J Mackett

touchREVIEWS in Neurology. 2024;20(2):Online ahead of journal publication

Neurometabolic Disease

New Treatment Option for Niemann-Pick Type B Disease

Published Online: Apr 22nd 2015

Beth Thurberg, MD, PhD, vice president of Pathology at Genzyme Corporation discusses the results of clinical trial looking at clearance of sphingomyelin with recombinant human acid sphingomyelinase administration in patients with Niemann-Pick Type B disease.

Tahseen Mozaffar: PROPEL Study Results Investigating the use of AT-GAA for the Treatment of Late-onset Pompe Disease

touchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]

Related Videos in Neurometabolic Disease

Antonio Federico, EAN 2018 – Effects of migration on the pathophysiology of neurological conditions

Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) describes the impact increased migration has had on the pathophysiology of neurological conditions and the need to increase awareness of this amongst neurologists. Questions 1. ...

Antonio Federico, EAN 2018 – Involvement of the EAN in rare neurological diseases

Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) discusses the unique challenges that rare neurological diseases bring and how the EAN have a Task Force focused on this important area. Questions 1. Could ...

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 2)

Günther Deuschl (EAN President; Professor of Neurology, Department of Neurology, University Hospital Schleswig-Holstein, Kiel Campus, Germany) kindly took the time to discuss with us the burden of neurological diseases in Europe, including disparities across our continent, and how the ...

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 1)

Thapanee Somboon, AAN 2018 – Neurology and sleep-disordered breathing/sleep apnea

Thapanee Somboon (Cleveland Clinic, OH) talks us through the key findings of her two presentations, which focused on the prevalence of high risk obstructive sleep apnea and insomnia in neurological populations (abstract available here) and the performance of sleep apnea ...

New Antisense Therapy in Development for Pompe Disease

In this exclusive interview during WORLDSymposium 2015, Nicholas Clayton, MSc, staff scientist at Genzyme Corporation discusses the exciting new data he and his colleagues presented on antisense therapy that is in development to treat patients with Pompe disease.

Niemann-Pick Disease Type C

Dr. Marc Patterson a pediatric neurologist at Mayo Clinic discusses Niemann-Pick disease type C.

Pompe Disease

Priya Kishnani, MD, professor of Pediatrics at Duke University School of Medicine and practicing geneticist at Duke Children's Hospital discusses our current understanding of the pathophysiology and management of Pompe disease.